Corbus Pharmaceuticals Holdings, Inc. earnings per share and revenue
On 12 de nov. de 2025, CRBP reported earnings of -1.90 USD per share (EPS) for Q3 25, missing the estimate of -1.74 USD, resulting in a -9.11% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analistas forecast an EPS of -1.67 USD, with revenue projected to reach 2.04 milhão USD, implying an diminuir of -12.11% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
What were Corbus Pharmaceuticals Holdings, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Corbus Pharmaceuticals Holdings, Inc. reported EPS of -$1.90, missing estimates by -9.11%, and revenue of $0.00, 0% as expectations.
How did the market react to Corbus Pharmaceuticals Holdings, Inc.'s Q3 2025 earnings?
The stock price moved up 7.39%, changed from $10.42 before the earnings release to $11.19 the day after.
When is Corbus Pharmaceuticals Holdings, Inc. expected to report next?
The next earning report is scheduled for 09 de mar. de 2026.
What are the forecasts for Corbus Pharmaceuticals Holdings, Inc.'s next earnings report?
Based on 12
analistas, Corbus Pharmaceuticals Holdings, Inc. is expected to report EPS of -$1.67 and revenue of $2.04M for Q4 2025.